Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2541-2550 Newer>

The Motley Fool November 22, 2005 Brian Gorman	Saying No to Drugs Britain's policy of restricting drug access based on cost-benefit analyses should be on the radar screen of pharmaceutical investors.
BusinessWeek November 28, 2005 Arlene Weintraub	My, How You've Grown A wave of drugs for short kids is sparking social controversy -- and an expanding market. Growth hormones are likely to remain in the spotlight for another reason: They could become the first-ever biotech drugs to become available in generic form.
BusinessWeek November 28, 2005 Kerry Capell	High-Velocity Vaccines PowderMed says its DNA technology would let it react quickly to a flu pandemic. A DNA flu vaccine would have huge advantages over traditional ones. But first, the company must prove in upcoming large-scale clinical trials that its vaccine can protect people from flu generally.
InternetNews November 15, 2005 Susan Kuchinskas	Keeping Drugs Legit With RFID Sun Microsystems released an RFID package focused on helping pharmaceutical companies track and authenticate drugs.
The Motley Fool November 15, 2005 Stephen D. Simpson	Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note.
Pharmaceutical Executive November 1, 2005 Sara Calabro	Valeant Pharmaceuticals is Soldiering On Valeant Pharmaceuticals' new CEO Tim Tyson restructures the company after legal and financial troubles.
Pharmaceutical Executive November 1, 2005 Patrick Clinton	Are We Aligned Yet? A Medicare Part D Roundtable The most salient feature of the Medicare prescription drug benefit is its uncertainties.
Pharmaceutical Executive November 1, 2005 Rubinstein & Galardi	Bustin' a CAP: The Competative Acquisition Program The new Competitive Acquisition Program for Medicare Part B drugs aims to align market forces with the distribution of drugs and biologics that doctors administer in their offices, but increasing bureaucracy is a major downside.
Pharmaceutical Executive November 1, 2005 Alana Klein	Direct to Consumer: A Q&A with Jim Hoyes Multiple sclerosis patients can benefit from a new kind of support system.
Pharmaceutical Executive November 1, 2005 Mike Luby	Marketing to Professionals: Detailing Attention to Details: The detail piece is a powerful sales tool when utilized and tested properly.
<Older 2541-2550 Newer> Return to current articles.